ABL1 and leukemia: This could not have been predicted based on sequencing of the ATP binding site of the oncogene that drives these leukemias: both BLQ1 and BLQ5 were isolated from patients who had relapsed and both contain the Abl T315I point mutation but lack other additional mutations in the ATP binding site that could explain differential resistance to ponatinib [38, 39].